Syntara Limited (@syntaratx) 's Twitter Profile
Syntara Limited

@syntaratx

Syntara (ASX:SNT) is an ASX-listed clinical stage drug developer for diseases linked to fibrosis and inflammation.

ID: 66560841

linkhttps://syntaratx.com.au/ calendar_today18-08-2009 01:51:28

453 Tweet

450 Followers

231 Following

Syntara Limited (@syntaratx) 's Twitter Profile Photo

On Clinical Trials Day, we want to recognise the people at the heart of every study - the patients, their families, the clinicians, and the research teams who make it possible. At Syntara, we’re especially grateful to those taking part in our trials for myelofibrosis and

On Clinical Trials Day, we want to recognise the people at the heart of every study - the patients, their families, the clinicians, and the research teams who make it possible.
At Syntara, we’re especially grateful to those taking part in our trials for myelofibrosis and
Syntara Limited (@syntaratx) 's Twitter Profile Photo

“This would be the first approved drug that’s modifying the whole way that a scar develops.” Thank you to 7NEWS Australia and reporter Amber Laidler for covering our work to change what’s possible in the treatment of scarring. Our next-generation topical anti-fibrotic drug is

Syntara Limited (@syntaratx) 's Twitter Profile Photo

Our CEO Gary Phillips, will be attending #BIO2025 in Boston from 16–19 June. If you’d like to connect during the event, please reach out to arrange a meeting. Learn more about the event: convention.bio.org #Biotech $SNT #Syntara #Myelofibrosis #SkinScarring

Our CEO Gary Phillips, will be attending #BIO2025 in Boston from 16–19 June.

If you’d like to connect during the event, please reach out to arrange a meeting.

Learn more about the event: convention.bio.org

#Biotech $SNT #Syntara #Myelofibrosis #SkinScarring
Syntara Limited (@syntaratx) 's Twitter Profile Photo

SNT-5505 has been granted Fast Track designation by the US FDA for the treatment of myelofibrosis. This designation enables more frequent FDA interaction, eligibility for Priority Review and discussions on accelerated approval and reflects both the strength of our clinical data

SNT-5505 has been granted Fast Track designation by the US FDA for the treatment of myelofibrosis.

This designation enables more frequent FDA interaction, eligibility for Priority Review and discussions on accelerated approval and reflects both the strength of our clinical data
Syntara Limited (@syntaratx) 's Twitter Profile Photo

🗞️FDA grants Fast Track designation for Syntara's SNT-5505 | Media coverage by AusBiotech. biotechdispatch.com.au/news/us-fda-fa… $SNT #ASX #ASXNews #Biotech #BiotechNews #Myelofibrosis

Syntara Limited (@syntaratx) 's Twitter Profile Photo

Syntara will present interim data from its ongoing Phase 2 trial of SNT-5505 in combination with ruxolitinib for the treatment of myelofibrosis at the 30th European Hematology Association (EHA) Congress in Milan, Italy. The poster presentation is scheduled for Saturday, 14 June,

Syntara will present interim data from its ongoing Phase 2 trial of SNT-5505 in combination with ruxolitinib for the treatment of myelofibrosis at the 30th European Hematology Association (EHA) Congress in Milan, Italy. The poster presentation is scheduled for Saturday, 14 June,
Syntara Limited (@syntaratx) 's Twitter Profile Photo

We will hold an investor webinar at 11:00am AEST on Friday 13 June to discuss new interim data from the ongoing Phase 2 study of SNT-5505 in myelofibrosis. The announcement of the latest interim data is being lodged on the ASX pre-market open today, Friday 13 June 2025, ahead of

We will hold an investor webinar at 11:00am AEST on Friday 13 June to discuss new interim data from the ongoing Phase 2 study of SNT-5505 in myelofibrosis.

The announcement of the latest interim data is being lodged on the ASX pre-market open today, Friday 13 June 2025, ahead of
Syntara Limited (@syntaratx) 's Twitter Profile Photo

We've reported further positive interim results from our ongoing Phase 2 trial of SNT-5505 in combination with ruxolitinib for the treatment of myelofibrosis. 73% of evaluable patients achieved a ≥50% reduction in total symptom score and 44% achieved a ≥25% spleen volume

We've reported further positive interim results from our ongoing Phase 2 trial of SNT-5505 in combination with ruxolitinib for the treatment of myelofibrosis.

73% of evaluable patients achieved a ≥50% reduction in total symptom score and 44% achieved a ≥25% spleen volume
Syntara Limited (@syntaratx) 's Twitter Profile Photo

EHA 2025: SNT-5505 Interim Data Presentation View the full $SNT Presentation here: cdn-api.markitdigital.com/apiman-gateway… #SNT #Syntara #Biotech #ASX #ASXnews

EHA 2025: SNT-5505 Interim Data Presentation
View the full $SNT Presentation here: cdn-api.markitdigital.com/apiman-gateway…
#SNT #Syntara #Biotech #ASX #ASXnews
Syntara Limited (@syntaratx) 's Twitter Profile Photo

Our CEO Gary Phillips is in Milan for the 30th European #Hematology Association Congress (EHA2025). It’s a great chance to connect with clinicians, researchers & partners as we share new interim data from our Phase 2 trial of SNT-5505 in #myelofibrosis. $SNT #Biotech #EHA2025

Our CEO Gary Phillips is in Milan for the 30th European #Hematology Association Congress (EHA2025). It’s a great chance to connect with clinicians, researchers & partners as we share new interim data from our Phase 2 trial of SNT-5505 in #myelofibrosis.
$SNT #Biotech #EHA2025
Syntara Limited (@syntaratx) 's Twitter Profile Photo

In case you missed it: We recently held an investor webinar where our CEO Gary Phillips, provided an update on Syntara’s latest positive interim data from the Phase 2 study of SNT-5505 in myelofibrosis. You can watch the full replay here: us02web.zoom.us/webinar/regist… Thank you to

In case you missed it: We recently held an investor webinar where our CEO Gary Phillips, provided an update on Syntara’s latest positive interim data from the Phase 2 study of SNT-5505 in myelofibrosis.

You can watch the full replay here: us02web.zoom.us/webinar/regist…

Thank you to
Syntara Limited (@syntaratx) 's Twitter Profile Photo

Syntara advances #myelofibrosis trial with Phase 2 data and SNT-5505 FDA fast track designation | $SNT Media coverage by Small Caps. smallcaps.com.au/syntara-myelof… #myelofibrosis #SNT #Syntara #Biotech

Syntara Limited (@syntaratx) 's Twitter Profile Photo

Closing out a successful week of partnering meetings at #BIO2025 in Boston. A big thanks to everyone who took the time to connect with us and to Bio for bringing together such a strong group. $SNT #Syntara #bloodcancer #Biotech

Closing out a successful week of partnering meetings at #BIO2025 in Boston.

A big thanks to everyone who took the time to connect with us and to Bio for bringing together such a strong group.

$SNT #Syntara #bloodcancer #Biotech
Syntara Limited (@syntaratx) 's Twitter Profile Photo

"I like to think of it as maybe best-in-class safety and tolerability of all the drugs being developed in myelofibrosis.” CEO Gary Phillips. In this short clip from our recent Q&A video update, Gary explains why haematologists at EHA2025 were encouraged by the latest interim

Syntara Limited (@syntaratx) 's Twitter Profile Photo

We've been granted an International Non-Proprietary Name (INN) by the World Health Organization for our lead clinical asset, SNT-5505, now officially named Amsulostat. The INN designation is a globally recognised milestone in the drug development process, supporting clear

We've been granted an International Non-Proprietary Name (INN) by the World Health Organization for our lead clinical asset, SNT-5505, now officially named Amsulostat.

The INN designation is a globally recognised milestone in the drug development process, supporting clear
Syntara Limited (@syntaratx) 's Twitter Profile Photo

WHO grants official INN for Syntara’s clinical development asset SNT-5505 | Media coverage by AusBiotech. biotechdispatch.com.au/news/who-grant… $SNT #Syntara #Biotech